GlassScriptPhysician profile
Kenneth L Saul
NPI 1760453401
$36,289.49
in general payments reported to CMS, 2019-2025
13 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,944 · 2020: $2,635 · 2021: $152 · 2022: $112 · 2023: $297 · 2024: $6,336 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $5,355 · Travel and Lodging: $3,259 · Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,140.00 |
| Consulting Fee | $5,355.00 |
| Travel and Lodging | $3,258.83 |
| Food and Beverage | $2,691.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $15,874.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $11,421.20 | 2022-2025 | Penmenvy |
| Sobi, INC | $7,505.34 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $276.81 | 2021-2025 | Qelbree |
| Novo Nordisk INC | $221.98 | 2024-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $221.86 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $186.71 | 2023-2025 | Enflonsia, Vaxneuvance |
| Kls-Martin L.P. | $180.13 | 2024 | |
| Tris Pharma INC | $154.43 | 2019-2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Sanofi-Aventis U.S. LLC | $121.27 | 2025 | |
| Genzyme Corporation | $81.50 | 2024 | |
| Coopersurgical, INC. | $23.81 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $19.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Saul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.